BIOMAT Database Logo BIOMAT Database Logo

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. 2010

Edus H Warren, and Nobuharu Fujii, and Yoshiki Akatsuka, and Colette N Chaney, and Jeffrey K Mito, and Keith R Loeb, and Ted A Gooley, and Michele L Brown, and Kevin K W Koo, and Kellie V Rosinski, and Seishi Ogawa, and Aiko Matsubara, and Frederick R Appelbaum, and Stanley R Riddell
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. ehwarren@u.washington.edu

The adoptive transfer of donor T cells that recognize recipient minor histocompatibility antigens (mHAgs) is a potential strategy for preventing or treating leukemic relapse after allogeneic hematopoietic cell transplantation (HCT). A total of 7 patients with recurrent leukemia after major histocompatibility complex (MHC)-matched allogeneic HCT were treated with infusions of donor-derived, ex vivo-expanded CD8(+) cytotoxic T lymphocyte (CTL) clones specific for tissue-restricted recipient mHAgs. The safety of T-cell therapy, in vivo persistence of transferred CTLs, and disease response were assessed. Molecular characterization of the mHAgs recognized by CTL clones administered to 3 patients was performed to provide insight into the antileukemic activity and safety of T-cell therapy. Pulmonary toxicity of CTL infusion was seen in 3 patients, was severe in 1 patient, and correlated with the level of expression of the mHAg-encoding genes in lung tissue. Adoptively transferred CTLs persisted in the blood up to 21 days after infusion, and 5 patients achieved complete but transient remissions after therapy. The results of these studies illustrate the potential to selectively enhance graft-versus-leukemia activity by the adoptive transfer of mHAg-specific T-cell clones and the challenges for the broad application of this approach in allogeneic HCT. This study has been registered at http://clinicaltrials.gov as NCT00107354.

UI MeSH Term Description Entries
D007124 Immunoenzyme Techniques Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens. Antibody Enzyme Technique, Unlabeled,Enzyme Immunoassay,Enzyme-Labeled Antibody Technique,Immunoassay, Enzyme,Immunoperoxidase Techniques,Peroxidase-Antiperoxidase Complex Technique,Peroxidase-Labeled Antibody Technique,Antibody Enzyme Technic, Unlabeled,Enzyme-Labeled Antibody Technic,Immunoenzyme Technics,Immunoperoxidase Technics,Peroxidase-Antiperoxidase Complex Technic,Peroxidase-Labeled Antibody Technic,Antibody Technic, Enzyme-Labeled,Antibody Technic, Peroxidase-Labeled,Antibody Technics, Enzyme-Labeled,Antibody Technics, Peroxidase-Labeled,Antibody Technique, Enzyme-Labeled,Antibody Technique, Peroxidase-Labeled,Antibody Techniques, Enzyme-Labeled,Antibody Techniques, Peroxidase-Labeled,Enzyme Immunoassays,Enzyme Labeled Antibody Technic,Enzyme Labeled Antibody Technique,Enzyme-Labeled Antibody Technics,Enzyme-Labeled Antibody Techniques,Immunoassays, Enzyme,Immunoenzyme Technic,Immunoenzyme Technique,Immunoperoxidase Technic,Immunoperoxidase Technique,Peroxidase Antiperoxidase Complex Technic,Peroxidase Antiperoxidase Complex Technique,Peroxidase Labeled Antibody Technic,Peroxidase Labeled Antibody Technique,Peroxidase-Antiperoxidase Complex Technics,Peroxidase-Antiperoxidase Complex Techniques,Peroxidase-Labeled Antibody Technics,Peroxidase-Labeled Antibody Techniques,Technic, Enzyme-Labeled Antibody,Technic, Immunoenzyme,Technic, Immunoperoxidase,Technic, Peroxidase-Antiperoxidase Complex,Technic, Peroxidase-Labeled Antibody,Technics, Enzyme-Labeled Antibody,Technics, Immunoenzyme,Technics, Immunoperoxidase,Technics, Peroxidase-Antiperoxidase Complex,Technics, Peroxidase-Labeled Antibody,Technique, Enzyme-Labeled Antibody,Technique, Immunoenzyme,Technique, Immunoperoxidase,Technique, Peroxidase-Antiperoxidase Complex,Technique, Peroxidase-Labeled Antibody,Techniques, Enzyme-Labeled Antibody,Techniques, Immunoenzyme,Techniques, Immunoperoxidase,Techniques, Peroxidase-Antiperoxidase Complex,Techniques, Peroxidase-Labeled Antibody
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Edus H Warren, and Nobuharu Fujii, and Yoshiki Akatsuka, and Colette N Chaney, and Jeffrey K Mito, and Keith R Loeb, and Ted A Gooley, and Michele L Brown, and Kevin K W Koo, and Kellie V Rosinski, and Seishi Ogawa, and Aiko Matsubara, and Frederick R Appelbaum, and Stanley R Riddell
Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation.
June 2023, American journal of hematology,
Edus H Warren, and Nobuharu Fujii, and Yoshiki Akatsuka, and Colette N Chaney, and Jeffrey K Mito, and Keith R Loeb, and Ted A Gooley, and Michele L Brown, and Kevin K W Koo, and Kellie V Rosinski, and Seishi Ogawa, and Aiko Matsubara, and Frederick R Appelbaum, and Stanley R Riddell
A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation.
January 2021, Frontiers in immunology,
Edus H Warren, and Nobuharu Fujii, and Yoshiki Akatsuka, and Colette N Chaney, and Jeffrey K Mito, and Keith R Loeb, and Ted A Gooley, and Michele L Brown, and Kevin K W Koo, and Kellie V Rosinski, and Seishi Ogawa, and Aiko Matsubara, and Frederick R Appelbaum, and Stanley R Riddell
Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.
March 2011, Immunology and cell biology,
Edus H Warren, and Nobuharu Fujii, and Yoshiki Akatsuka, and Colette N Chaney, and Jeffrey K Mito, and Keith R Loeb, and Ted A Gooley, and Michele L Brown, and Kevin K W Koo, and Kellie V Rosinski, and Seishi Ogawa, and Aiko Matsubara, and Frederick R Appelbaum, and Stanley R Riddell
[Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
July 2008, Deutsche medizinische Wochenschrift (1946),
Edus H Warren, and Nobuharu Fujii, and Yoshiki Akatsuka, and Colette N Chaney, and Jeffrey K Mito, and Keith R Loeb, and Ted A Gooley, and Michele L Brown, and Kevin K W Koo, and Kellie V Rosinski, and Seishi Ogawa, and Aiko Matsubara, and Frederick R Appelbaum, and Stanley R Riddell
Targeting alloreactive T cells to hematopoietic system specific minor histocompatibility antigens for cellular immunotherapy of hematological malignancies after stem cell transplantation.
January 2002, Annals of hematology,
Edus H Warren, and Nobuharu Fujii, and Yoshiki Akatsuka, and Colette N Chaney, and Jeffrey K Mito, and Keith R Loeb, and Ted A Gooley, and Michele L Brown, and Kevin K W Koo, and Kellie V Rosinski, and Seishi Ogawa, and Aiko Matsubara, and Frederick R Appelbaum, and Stanley R Riddell
Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation.
November 1998, Current opinion in hematology,
Edus H Warren, and Nobuharu Fujii, and Yoshiki Akatsuka, and Colette N Chaney, and Jeffrey K Mito, and Keith R Loeb, and Ted A Gooley, and Michele L Brown, and Kevin K W Koo, and Kellie V Rosinski, and Seishi Ogawa, and Aiko Matsubara, and Frederick R Appelbaum, and Stanley R Riddell
Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.
April 1999, Blood,
Edus H Warren, and Nobuharu Fujii, and Yoshiki Akatsuka, and Colette N Chaney, and Jeffrey K Mito, and Keith R Loeb, and Ted A Gooley, and Michele L Brown, and Kevin K W Koo, and Kellie V Rosinski, and Seishi Ogawa, and Aiko Matsubara, and Frederick R Appelbaum, and Stanley R Riddell
Analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation.
May 2003, Bone marrow transplantation,
Edus H Warren, and Nobuharu Fujii, and Yoshiki Akatsuka, and Colette N Chaney, and Jeffrey K Mito, and Keith R Loeb, and Ted A Gooley, and Michele L Brown, and Kevin K W Koo, and Kellie V Rosinski, and Seishi Ogawa, and Aiko Matsubara, and Frederick R Appelbaum, and Stanley R Riddell
Second allogeneic transplantation for relapsed acute leukemia after initial allogeneic hematopoietic stem cell transplantation.
October 2012, Pathology oncology research : POR,
Edus H Warren, and Nobuharu Fujii, and Yoshiki Akatsuka, and Colette N Chaney, and Jeffrey K Mito, and Keith R Loeb, and Ted A Gooley, and Michele L Brown, and Kevin K W Koo, and Kellie V Rosinski, and Seishi Ogawa, and Aiko Matsubara, and Frederick R Appelbaum, and Stanley R Riddell
Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
March 2021, Clinical transplantation,
Copied contents to your clipboard!